Compounds > phenylalanine

phenylalanine and dasatinib

phenylalanine has been researched along with dasatinib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N1
Divoka, M; Divoky, V; Faber, E; Indrak, K; Jarosova, M; Mojzikova, R; Plachy, R; Rozmanova, S; Stastny, M1
Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O1
Hååg, P; Holmsten, K; Juntti, T; Kanter, L; Lewensohn, R; Shah, CH; Sierakowiak, A; Spira, J; Tu, J; Ullén, A; Viktorsson, K; Zielinska-Chomej, K1

Other Studies

4 other study(ies) available for phenylalanine and dasatinib

ArticleYear
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Adult; Antineoplastic Agents; Blast Crisis; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure

2006
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Amino Acid Substitution; Antineoplastic Agents; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylalanine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles; Treatment Outcome

2010
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
    Leukemia research, 2012, Volume: 36, Issue:1

    Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome

2012
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
    Molecular oncology, 2016, Volume: 10, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Dasatinib; Humans; Melphalan; Phenylalanine; Protein Kinase Inhibitors; src-Family Kinases; Urologic Neoplasms; Urothelium

2016